Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström MacroglobulinemiaGlobeNewsWire · Oct 15, 2026
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström MacroglobulinemiaGlobeNewsWire · Sep 29, 2026
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy TranscriptSeeking Alpha · Aug 18, 2026
Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 13, 2026
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewsWire · Aug 13, 2026
Analysts Set Cellectar Biosciences, Inc. (NASDAQ:CLRB) PT at $11.00Defense World · Aug 11, 2026Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.52 | -$0.57 | Miss |
| May 14, 2026 | -$1.89 | -$1.33 | Beat |
| Mar 4, 2026 | -$1.19 | -$0.53 | Beat |
| Nov 13, 2025 | -$1.91 | -$1.41 | Beat |
| Aug 14, 2025 | -$3.60 | -$3.39 | Beat |
| May 13, 2025 | -$5.11 | -$3.90 | Beat |